(Q35889586)

10 August 2017

1 reference

title

Antivirals and antiviral strategies (English)

1 reference

10 August 2017

Erik De Clercq

1

0 references

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Nature Reviews Microbiology

10 August 2017

published in

1 reference

10 August 2017

volume

2

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

704-720

1 reference

Strategies in the design of antiviral drugs

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Antiviral drugs in current clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Structure-activity relationships of (S,Z)-2-aminopurine methylenecyclopropane analogues of nucleosides. Variation of purine-6 substituents and activity against herpesviruses and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

New anti-HSV therapeutics target the helicase-primase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

An overview on the use of a viral pathogen as a bioterrorism agent: why smallpox?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

A review of compounds exhibiting anti-orthopoxvirus activity in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Cidofovir in the treatment of poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Efficacy of cidofovir in a murine model of disseminated progressive vaccinia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Entecavir, FTC, L-FMAU, LdT and others

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Treatment of potentially life-threatening enterovirus infections with pleconaril

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Prospects for antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Identification of active antiviral compounds against a New York isolate of West Nile virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Arenaviruses other than Lassa virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Defense against filoviruses used as biological weapons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Hepatitis C therapeutics: current status and emerging strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Mechanism of action of a pestivirus antiviral compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Specific Inhibition of Bovine Viral Diarrhea Virus Replicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Ribonucleoside Analogue That Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

The potential use of influenza virus as an agent for bioterrorism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Rational design of potent sialidase-based inhibitors of influenza virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Nipah virus--a potential agent of bioterrorism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

A newly discovered human pneumovirus isolated from young children with respiratory tract disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

RFI-641, a potent respiratory syncytial virus inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Coronavirus as a possible cause of severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

A major outbreak of severe acute respiratory syndrome in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

A novel coronavirus associated with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Aetiology: Koch's postulates fulfilled for SARS virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5' to 3' viral helicases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

The bicyclam AMD3100 story

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Activities of various compounds against murine and primate polyomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Clinical uses of cidofovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Pleconaril: a novel antipicornaviral drug

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

31 March 2020

Tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Acute Encephalitis, a Poliomyelitis-like Syndrome and Neurological Sequelae in a Hamster Model for Flavivirus Infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Lassa fever. Effective therapy with ribavirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-1998. A 32-year-old woman with pharyngeal spasms and paresthesias after a dog bite

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Viral infection and host defense

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

SARS--beginning to understand a new virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Treatment of SARS with human interferons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Combination Therapy of AIDS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO975

Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56

31 March 2020

1 reference

PubMed

12 December 2020

Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials.

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

A novel, highly selective inhibitor of pestivirus replication that targets the viral RNA-dependent RNA polymerase

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1038/NRMICRO975

1 reference

10 August 2017

0 references

1 reference